Annual Clinical and Economic Burden of Medically Attended Lower Respiratory Tract Illnesses Due to Respiratory Syncytial Virus Among US Infants Aged <12 Months
We developed a model to project the expected annual clinical and economic burden of medically attended lower respiratory tract illnesses due to respiratory syncytial virus (RSV-LRTI) among United States (US) infants aged <12 months by combining information on population size, disease rates, mortality rates, and unit costs. Among the 3.7 million US infants aged <12 months each year, a total of 592 700 cases of RSV-LRTI (hospitalizations: 48 499; emergency department visits: 144 599; outpatient clinic visits: 399 602) were projected to occur, yielding total annual costs of $1.6 billion. The annual burden of RSV-LRTI among US infants is considerable, especially among those aged <3 months, who account for 43% of total costs.
Authors
- Kimberly M. Shea (ORCID: https://orcid.org/0000-0002-8760-5357)
- Linnea Houde
- Derek Weycker (ORCID: https://orcid.org/0000-0002-5405-2215)
- Sarah Pugh (ORCID: https://orcid.org/0000-0003-4347-2561)
- Ahuva Averin (ORCID: https://orcid.org/0000-0002-4490-7021)
- Alejandro Cané (ORCID: https://orcid.org/0000-0003-0778-6862)
- Amy Law
Institutions
- Pfizer (United States) (US)
- Prevea Health (US)
- Global Policy Institute (US)
Publication Details
- Journal
- The Journal of Infectious Diseases
- Published
- 2024-11-15
- DOI
- https://doi.org/10.1093/infdis/jiae544
- Citations
- 7
- Primary Topic
- Respiratory viral infections research
- Type
- article
- Field-Weighted Citation Impact
- 2.71
Funders
- Pfizer
- Instituto Nacional de Cancerología